Since 2014, the pharmacological use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which mimic the gut hormone GLP-1, has provided an alternative to lifestyle interventions for tackling obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.